Key result
Co-administration of simvastatin and microdystrophin gene therapy did not demonstrate an additive beneficial effect in the mdx mouse model for Duchenne muscular dystrophy.
Why the study?
Gene therapy for DMD yields unsatisfactory clinical benefit, possibly because secondary metabolic pathologies are not fully corrected by dystrophin restoration alone.
Does the combination of microdystrophin gene therapy and simvastatin improve outcomes in the mdx mouse model for Duchenne muscular dystrophy?
Does the combination of microdystrophin gene therapy and simvastatin improve outcomes in the mdx mouse model for Duchenne muscular dystrophy?
Combining dystrophin restoration with metabolic normalization by simvastatin does not provide an additive beneficial effect in the mdx mouse model of Duchenne muscular dystrophy.
Duchenne muscular dystrophy (DMD) is the most common and cureless muscle pediatric genetic disease, which is caused by the lack or the drastically reduced expression of dystrophin. Experimental therapeutic approaches for DMD have been mainly focused in recent years on attempts to restore the expression of dystrophin. While significant progress was achieved, the therapeutic benefit of treated patients is still unsatisfactory. Efficiency in gene therapy for DMD is hampered not only by incompletely resolved technical issues, but likely also due to the progressive nature of DMD. It is indeed suspected that some of the secondary pathologies, which are evolving over time in DMD patients, are not fully corrected by the restoration of dystrophin expression. We recently identified perturbations of the mevalonate pathway and of cholesterol metabolism in DMD patients. Taking advantage of the mdx model for DMD, we then demonstrated that some of these perturbations are improved by treatment with the cholesterol-lowering drug, simvastatin. In the present investigation, we tested whether the combination of the restoration of dystrophin expression with simvastatin treatment could have an additive beneficial effect in the mdx model. We confirmed the positive effects of microdystrophin, and of simvastatin, when administrated separately, but detected no additive effect by their combination. Thus, the present study does not support an additive beneficial effect by combining dystrophin restoration with a metabolic normalization by simvastatin.
No takes yet. Share an insight, caveat, or question.
Bourg et al. (2022) studied Duchenne muscular dystrophy (mdx mouse model). Microdystrophin gene therapy combined with simvastatin vs. Microdystrophin or simvastatin alone was evaluated on Additive beneficial effect. Co-administration of simvastatin and microdystrophin gene therapy did not demonstrate an additive beneficial effect in the mdx mouse model for Duchenne muscular dystrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: